Synthesis and biological evaluation of norcantharidin analogues: Towards PP1 selectivity

Scott G. Stewart, Timothy A. Hill, Jayne Gilbert, Stephen P. Ackland, Jennette A. Sakoff, Adam McCluskey

Research output: Contribution to journalArticle

41 Citations (Scopus)

Abstract

Simple modi. cations to the anhydride moiety of norcantharidin have lead to the development of a series of analogues displaying modest PP1 inhibition (low mu M IC(50)s) comparable to that of norcantharidin (PP1 IC50 = 10.3 +/- 1.37 mu M). However, unlike norcantharidin, which is a potent inhibitor of PP2A (IC50 = 2.69 +/- 1.37 mu M), these analogues show reduced PP2A inhibitory action resulting in the development of selective PP1 inhibitory compounds. Data indicates that the introduction of two ortho-disposed substituents on an aromatic ring, or para-substituent favours PP1 inhibition over PP2A inhibition. Introduction of a p-morphilinoaniline substituent, 35, affords an inhibitor displaying PP1 IC50 = 6.5 +/- 2.3 mu M; and PP2A IC50 = 7.9 +/- 0.82 mu M (PP1/PP2A = 0.82); and a 2,4,6-trimethylaniline, 23, displaying PP1 IC50 = 48 +/- 9; and PP2A IC5 85 +/- 3 mu M (PP1/PP2A = 0.56). The latter shows a 7-fold improvement in PP1 versus PP2A selectivity when compared with norcantharidin. Subsequent analysis of 23 and 35 as potential PP2B inhibitors revealed modest inhibition with IC(50)s of 89 +/- 6 and 42 +/- 3 mu M, respectively, and returned with PP1/PP2B selectivities of 0.54 and 0.15. Thus, these analogues are the simplest and most selective PP1 inhibitors retaining potency reported to date. Crown copyright (C) 2007 Published by Elsevier Ltd. All rights reserved.

Original languageEnglish
Pages (from-to)7301-7310
Number of pages10
JournalBioorganic & Medicinal Chemistry
Volume15
Issue number23
DOIs
Publication statusPublished - 1 Dec 2007

Cite this